BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BB-1705’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BB-1705 overview

BB-1705 is under development for solid tumor, triple-negative breast cancer, head and neck cancer, non-small cell lung cancer (NSCLC), gastric cancer and unspecified cancer. The drug candidate is a Eribulin-ADC. It acts by targeting epidermal growth factor receptor (EGFR) and is administered through intravenous route of administration.

Bliss Biopharmaceutical (Hangzhou) overview

Bliss Biopharmaceutical (Hangzhou) is a biopharmaceutical company engaged in research, discovery, development and commercialization of anti-tumor macromolecular biotherapeutics and novel drugs for the treatment of various cancer diseases. The company is headquartered in Hangzhou, Zhejiang, China.

For a complete picture of BB-1705’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.